A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study (called DLLEVATE) is comparing a new drug called ZL-1310 against the doctor's choice of treatment for people with small cell lung cancer (SCLC) that has come back after initial treatment. Small cell lung cancer is a fast-growing form of lung cancer that often returns after first-line therapy.
**You may be eligible if...**
- You are 18 or older and have been confirmed to have small cell lung cancer
- Your cancer has come back or worsened after receiving first-line platinum-based chemotherapy, or after second-line tarlatamab treatment
- Your cancer can be measured on a scan
- You are generally healthy enough to undergo treatment (ECOG performance status 0 or 1)
- Your life expectancy is at least 3 months
- You are willing to provide a tumor biopsy or archived tissue sample
**You may NOT be eligible if...**
- You have received more than one prior line of chemotherapy for extensive-stage SCLC
- You have previously received certain antibody-drug conjugates (ADCs) with a topoisomerase 1 inhibitor
- You have a history of certain lung inflammation (ILD/pneumonitis)
- You have another active cancer
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZL-1310
ZL-1310 as a single-agent
DRUGInvestigator's Choice of Therapy
Topotecan or Amrubicin
Locations(155)
University of California San Diego
La Jolla, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
University of Colorado
Aurora, Colorado, United States
Yale Cancer Center/Clinical Trials Office
New Haven, Connecticut, United States
Clermont Oncology Center
Clermont, Florida, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
Cancer Centers of Bevard
Rockledge, Florida, United States
Sarah Cannon Research Institute
Sarasota, Florida, United States
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Florida Cancer Specialists - East
West Palm Beach, Florida, United States
Illinois Cancer Care
Peoria, Illinois, United States
OSF St. Francis Medical Center
Peoria, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
University of Iowa Mission Health Cancer + Blood
Waukee, Iowa, United States
Norton Cancer Institute
Louisville, Kentucky, United States
American Oncology Partners, PA - The Center for Cancer and Blood Disorders